#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/4gO7q71

On World Hepatitis Day, we’re raising awareness of viral hepatitis and recognizing the importance of early and more complete testing in hepatitis B. Learn more about complete testing at: hepatitisbtesting.com #WorldHepatitisDay #HepB #HepatitisB #LiverHealth #TestingMatters

Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge. Find out more: gsk.to/4pG56BQ #Q2Results $GSK

#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. Find out more in the press release: gsk.to/4fdROcs Our mission: to leave no person living with HIV behind.

#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: us.gsk.com/en-us/media/press…

#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/4eoSdHf

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/4dQBSLg.

Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management. At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.

News for #Investors and #Media Explore the key highlights from our Q1 2026 results announcement ⤵️ Find out more: gsk.to/4uelV7Y $GSK

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026. Find out more: gsk.to/3OA31JU $GSK #Q1Results

News for #Investors and #Media: Today, we announced the US Food and Drug Administration accepted our application for a potential first-in-class treatment for chronic hepatitis B. Learn more: gsk.to/4darMFN

Current treatments for #cUTIs caused by drug-resistant organisms often require hospitalization. The lack of oral treatments can result in extended hospital stays, ultimately having a negative impact on patients’ quality of life. We remain focused to address the growing issue of antimicrobial resistance. #ESCMIDGlobal2026

#News for #Investors and #Media: At #SGO2026, we presented new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/47V3hJO.

Our partnership with the lupus community has always been fueled by a clear purpose: to improve the outcomes for people living with lupus. This dedication to advancing breakthroughs continues to drive our work as we look ahead to the future of lupus care. #Lupus #AheadTogether

We‘ve topped the Access to Medicine Index's 2026 Antimicrobial Resistance Benchmark, reflecting our continuous focus on delivering innovative antibiotic medicines and vaccines for patients with significant unmet medical need. Check out our #AMR podcast: gsk.to/4rj3UUt

Our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders. Take a look at the highlights ⤵️ 🔗 Investors and media can read more: gsk.to/4ubX9pQ

We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more. If you can’t attend, you can learn more about our work here: gsk.me/4tYOfvR 🫁

Explore the key highlights from our Q4 and full year 2025 results announcement ⤵️ More information for media and investors: gsk.to/4a2WXQw $GSK